Ortho Biotech Products, L.P. revised the label for PROCRIT? (Epoetin alfa), acting upon guidance from the U.S. Food and Drug Administration (FDA) to revise labeling for all drugs within the erythropoiesis-stimulating agent (ESA) class.
People with chronic kidney disease are significantly more likely to have other, life-threatening conditions such as heart disease, according to new findings from a nationwide screening program by the National Kidney Foundation (NKF) published in the March issue of the American Journal of Kidney Diseases.
The U.S. Food and Drug Administration (FDA) issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
People with chronic kidney disease are significantly more likely to have other, life-threatening conditions such as heart disease, according to new findings from a nationwide screening program by the National Kidney Foundation (NKF) published in the March issue of the American Journal of Kidney Diseases.
The Broad Institute of MIT and Harvard has received a $100 million gift to launch a new research center that will combine the strengths of genomics and chemical biology to advance the understanding and treatment of severe mental illnesses.
An article published in ‘The Lancet’ by researchers from the Menzies School of Health Research (MSHR) in Darwin has revealed a breakthrough in the battle to treat Malaria ? a disease which effects 40 per cent of the worlds population.
On International Women’s Day, the UK National AIDS Trust calls for further support for the development of microbicides and vaccines, new prevention technologies that could prevent millions of women from becoming infected with HIV.
Novartis announced that the United States has become the first country in the world to approve Tekturna? (aliskiren), the first new type of medicine in more than a decade for treating high blood pressure – a condition estimated to affect nearly one billion people worldwide and still uncontrolled in nearly 70% of patients.
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Lipitor? (atorvastatin calcium) Tablets to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.
Worldwide people are undersupplied with vitamin D3, which has a key role in bone and calcium metabolism. Shortages can cause Osteoporosis which is a global public health problem with an estimated cost of $19 billion annually.